Hematologic Oncology

Primary investigator Bijal Shah, MD, MS, shares insights into the efficacy results of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy for acute lymphocytic leukemia (ALL), and Eunice Wang, MD, reviews the trial’s key safety data.

Leukemia experts provide an overview of the ZUMA-3 trial of chimeric antigen receptor (CAR) T-cell therapy in adult patients with relapsed/refractory acute lymphocytic leukemia (ALL) by discussing the overall study design and patient population.

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

An independent data monitoring committee has recommended that the phase 3 ARMADA 200 trial examining devimistat plus high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia continue as planned.

The FDA has approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) as part of a chemotherapy regimen to treat pediatric and adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma who are allergic to the E. coli-derived asparaginase products.

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Eunice Wang, MD, discusses the KOMET-001 trial, the potential for KO-539 to address an unmet need in acute myeloid leukemia, and the future of menin inhibition in this disease.

Julian Adams, PhD, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.

Key experts in hematology oncology discuss the use of MRD status to assess therapeutic response and guide treatment decisions in patients with relapsed/refractory ALL.  

Eunice Wang, MD and Bijal Shah, MD, MS, begin with an overview of novel agents and emerging therapeutic approaches for the treatment of acute lymphoblastic leukemia.  

The fixed combination of daunorubicin and cytarabine continued to demonstrate improved overall survival vs 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

A phase 1 study evaluating the off-the-shelf cell therapy CYNK-001 has expanded to include patients with relapsed/refractory acute myeloid leukemia after a case of conversion to minimal residual disease negativity at its highest dose level.

Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

Ehab Atallah, MD, spotlights recent updates, emerging approaches, and next steps for research in leukemia and lymphoma.

Loncastuximab tesirine-lpyl continued to demonstrate promising antitumor activity with an acceptable toxicity profile when used in the treatment of select patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma.

The European Commission has granted marketing authorization for the expanded use of subcutaneous daratumumab for use in 2 new indications.

Camidanlumab tesirine was found to elicit an objective response rate of 66.3% in patients with relapsed/refractory Hodgkin lymphoma.

Laura C. Michaelis, MD, discusses safety considerations with the combination of venetoclax and azacitidine in acute myeloid leukemia.

The expanding therapeutic landscape in multiple myeloma is poised to integrate daratumumab-based quadruplet therapies and novel cellular therapies as standard options for patients with newly diagnosed and relapsed/refractory disease.

The China National Medical Products Administration has granted a conditional approval to zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia who have previously received at least 1 therapy.

A supplemental new drug application and a marketing authorization application seeking the approval of the combination of copanlisib and rituximab for the treatment of patients with indolent non-Hodgkin lymphoma have been submitted to the FDA and the European Medicines Agency, respectively.